| pubmed-article:12888588 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0023290 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C1145701 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:12888588 | lifeskim:mentions | umls-concept:C1096768 | lld:lifeskim |
| pubmed-article:12888588 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12888588 | pubmed:dateCreated | 2003-9-5 | lld:pubmed |
| pubmed-article:12888588 | pubmed:abstractText | Optimal treatment for HIV-related visceral leishmaniasis (VL) has still to be established. A pilot clinical trial was carried out in 57 HIV-VL coinfected patients to compare the efficacy and safety of amphotericin B lipid complex (ABLC) versus meglumine antimoniate. The patients were randomized to receive either ABLC 3 mg/kg/day for 5 days (ABLC-5, 18 patients), ABLC 3 mg/kg/day for 10 days (ABLC-10, 20 patients) or meglumine antimoniate 20 mg Sbv /kg/day for 28 days (19 patients). Treatment was considered successful if parasites were not detected in a bone marrow aspirate after treatment. Parasitological cure was attained in 33% (95% CI: 13%-59%) of the ABLC-5 group, in 42% (95% CI: 16%-62%) of the ABLC-10 group and in 37% (95% CI: 16%-62%) of the meglumine antimoniate group (P = 0.94). Eight out of 19 patients administered antimoniate discontinued treatment prematurely following serious adverse events, compared with one in the ABLC groups (P = 0.0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC. | lld:pubmed |
| pubmed-article:12888588 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12888588 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12888588 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12888588 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12888588 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:ClotetBonaven... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:SireraGuillem... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:Torre-Cisnero... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:RiberaEsteban... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:LagunaFernand... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:AlvarJorgeJ | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:Spanish... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:VidelaSebasti... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:López-VélezRo... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:PradosDolores... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:Jiménez-Mejía... | lld:pubmed |
| pubmed-article:12888588 | pubmed:author | pubmed-author:SustMarianoM | lld:pubmed |
| pubmed-article:12888588 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12888588 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:12888588 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12888588 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12888588 | pubmed:pagination | 464-8 | lld:pubmed |
| pubmed-article:12888588 | pubmed:dateRevised | 2008-9-25 | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:meshHeading | pubmed-meshheading:12888588... | lld:pubmed |
| pubmed-article:12888588 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12888588 | pubmed:articleTitle | Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. | lld:pubmed |
| pubmed-article:12888588 | pubmed:affiliation | Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C/Sinesio Delgado 12, 28029-Madrid, Spain. flaguna@hotmail.com | lld:pubmed |
| pubmed-article:12888588 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12888588 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12888588 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12888588 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12888588 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12888588 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12888588 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12888588 | lld:pubmed |
